VistaGen Therapeutics, Inc. Forecast, price target & analysts
VistaGen Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
VistaGen Therapeutics, Inc. Classifications & Recommendation
VistaGen Therapeutics, Inc. Price Target
| Target Price | $1.02 |
| Price | $0.24 |
| Potential |
332.02%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target VistaGen Therapeutics, Inc. 2027 .
The average VistaGen Therapeutics, Inc. target price is $1.02.
This is
332.02%
register free of charge
$1.05
344.73%
register free of charge
$0.91
285.01%
register free of charge
|
|
| A rating was issued by 10 analysts: 0 Analysts recommend VistaGen Therapeutics, Inc. to buy, 7 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the VistaGen Therapeutics, Inc. stock has an average upside potential 2027 of
332.02%
register free of charge
|
Sales and Margin forecast 2027, 2028 to 2030
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.27 | 1.72 |
| 159.18% | 35.75% | |
| Net Margin | -5,487.40% | -3,872.95% |
| 47.71% | 29.42% |
4 Analysts have issued a sales forecast VistaGen Therapeutics, Inc. 2027 . The average VistaGen Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 VistaGen Therapeutics, Inc. Analysts have issued a net profit forecast 2027. The average VistaGen Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
| 2026 | -5,487.40% | 47.71% |
|---|---|---|
| 2027 |
-3,872.95%
29.42%
unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 to 2030
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.83 | -1.50 |
| 9.58% | 18.03% | |
| P/E | negative | |
| EV/Sales | negative |
5 Analysts have issued a VistaGen Therapeutics, Inc. forecast for earnings per share. The average VistaGen Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2027, the VistaGen Therapeutics, Inc. stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | -8.50 | 111.28% |
|---|---|---|
| 2027 |
-12.33
45.01%
unlock
|
|
P/S ratio
| Current | 4.19 | 97.53% |
|---|---|---|
| 2027 |
6.08
45.05%
unlock
|
|
VistaGen Therapeutics, Inc....
Current VistaGen Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Jefferies |
Locked
➜
Locked
|
Locked | Dec 17 2025 |
| Maxim Group |
Locked
➜
Locked
|
Locked | Dec 17 2025 |
| William Blair |
Locked
➜
Locked
|
Locked | Dec 17 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Jefferies:
Locked
➜
Locked
|
Dec 17 2025 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
Dec 17 2025 |
|
Locked
William Blair:
Locked
➜
Locked
|
Dec 17 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
